ESR2 and neoplasm: A phase II clinical trial (NCT03941730) aiming at the conundrum above was conducted in the ERβ-positive TNBC population, which traded off the activation of the tumor-suppression effect by E2 against the refrainment of the tumor-promoting effect by tamoxifen regarding the pros and cons of ERβ.